N., Yang, C., Han, C., Norinsky, R
According to the Phase 3b, double-blind, placebo-controlled STRIDE study, Ozempic (1 mg) resulted in a superior and clinically meaningful improvement of 13% in maximum walking distance and a mean treatment difference of 39.9 meters on a steep incline compared to placebo at week 52 in adults with T2DM and PAD. If approved, Ozempic will be the only GLP-1 receptor agonist indicated for the treatment of PAD in patients with T2DM
Does it help clear stress-induced brain fog so you feel less fatigued
A physician-led experiment Steven Klein, an addiction medicine specialist at Caron, is leading a pilot program that represents one of the most extensive real-world tests of GLP-1 drugs for addiction to date
So, what are the options for those seeking to access GLP-1s without excessive costs
The cardiovascular and metabolic benefits of these drugs are substantial for many patients